Crispr Therapeutics AG is a pioneering biotechnology company based in Zug, Switzerland, specializing in gene editing technologies. The organization focuses on developing innovative therapies that harness the power of CRISPR/Cas9 for various applications, including cancer treatment and the engineering of T cells and natural killer cells. Their research encompasses universal donor cells and advanced techniques such as PTPN2 knockout and chimeric antigen receptors, aiming to transform the landscape of genetic medicine and improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

86 Patents

#14 in Zug

#185 in Switzerland

#8,868 in the World

Zug, Switzerland

Crispr Therapeutics Ag

Forward Citations = 179

82 inventors:

Demetrios Kalaitzidis (26 out of 26 patents)

Alireza Rezania (23 out of 23 patents)

Jonathan Alexander Terrett (22 out of 36 patents)

4. Lawrence Klein (19 out of 25 patents)

5. Rebeca Ramos-Zayas (17 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Crispr Therapeutics Ag. Retrieved from https://idiyas.com/company/crispr-therapeutics-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

12 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]